ad-1208

AD-1208 is a first-in-class small molecule inhibitor targeting microtubule associated serine/threonine kinase like (MASTL). Developed by Avelos Therapeutics, it is designed to disrupt mitosis and the DNA damage response in cancer cells. The drug demonstrates selective inhibition of cancer cell growth in preclinical models and is being developed as an oral therapy for patients with advanced or refractory malignant solid tumors. Its mechanism of action involves inhibiting MASTL kinase activity, which plays a key role in cell cycle regulation and DNA repair pathways. Clinical trials are ongoing to evaluate its safety and efficacy as both a single agent and in combination therapies for various solid tumors[1][3][5].

Other names

AD1208AD-1208AD 1208